SEC Filing Analysis: DAXOR CORP (DXR)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: Daxor's Chief Scientific Officer, Jonathan Adam Feldschuh, was granted 18,000 shares of common stock, a transaction that increases his total holdings by 50%.
• Market Impact: The grant represents moderate shareholder dilution (0.37% of shares outstanding) and aligns the executive's interests with the company's performance. The market impact is expected to be neutral as this is a form of compensation.

Company Information

Field	Value
Company	DAXOR CORP
Ticker Symbol	DXR
CIK	0000027367
Market Cap	$60 million

Insider Information

Field	Value
Name	Feldschuh Jonathan Adam
CIK	0001701998
Title/Position	Chief Scientific Officer
Relationship	Director, Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-12-09
Transaction Code	P (Note: Filed as Purchase, but context indicates a Grant)
Security Type	Daxor Common Stock
Shares Involved	18,000
Price Per Share	$0.00
Total Value	$0
Shares Owned After	53,908
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.0%
Shares Transacted	18,000
% of Shares Outstanding	0.372%
Post-Transaction Ownership	53,908 shares (1.11% of outstanding)
Materiality Assessment	Moderate

Impact Evaluation

• Market Cap Context: For Daxor, a nano-cap company with a $60 million market capitalization, non-cash transactions involving share issuance are common for compensation. The significance is measured by dilution rather than dollar value.
• Ownership Concentration: The grant increases the insider's ownership from 35,908 shares (0.74%) to 53,908 shares (1.11%). This is a substantial 50% increase in his personal stake, strengthening his alignment with shareholder interests.
• Dilution Impact: The issuance of 18,000 new shares represents a 0.372% dilution to existing shareholders. While not trivial, this is a moderate level of dilution for a single executive grant in a company of this size.
• Transaction Significance: The transaction's significance is rated 'Medium'. Although the dollar value is zero, the number of shares granted is notable relative to the company's total shares outstanding (falling into the 0.25%-0.5% 'Significant' band), and it materially increases the insider's stake.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Stock grants are a standard form of executive compensation and do not typically signal new, non-public information about the company's immediate prospects. The market generally anticipates such grants.

Volume & Sentiment

• Expected Volume Impact: Minimal. As this is not an open-market transaction, it will not directly impact trading volume.
• Sentiment Indicator: Neutral. The grant is a routine corporate action that aligns incentives but also causes minor dilution.

Investment Insights

Positive Market Indicators

• Executive Alignment: The substantial increase in the CSO's holdings aligns his financial interests more closely with long-term shareholder value creation.

Risk Factors

• Shareholder Dilution: The grant contributes to the gradual dilution of existing shareholders' equity.

Key Takeaways

1. A key executive, the Chief Scientific Officer, received a significant stock grant, increasing his ownership by 50%.
2. The transaction represents a moderate 0.372% dilution to total shares outstanding.
3. The grant is a long-term incentive, as the shares do not vest until December 2025, tying the executive to future performance.

Additional Context

Transaction Notes

• Vesting Schedule: A footnote in the filing specifies that the 18,000 shares will vest one year after the grant date, on December 9, 2025.
• Filing Code: The transaction was coded as 'P' for Purchase, which is inconsistent with the $0 price and the footnote describing it as a grant. The more appropriate code would have been 'A' for Award.